Trial Profile
Biological Predictive Factors of Response to Erythropoiesis Stimulating Agent (ESA) in Low Risk Myelodysplastic Syndromes (MDS) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 31 Jul 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.